Spero Therapeutics (SPRO) Gains from Investment Securities (2016 - 2025)

Spero Therapeutics has reported Gains from Investment Securities for 10 years, with the latest figure at $2.4 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Investment Securities fell 14.72% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (changed 0.0% YoY), and the FY2025 full-year result was $2.4 million, down 14.72% from the prior year.
• Gains from Investment Securities for Q4 2025 stood at $2.4 million, up from $414417.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $5.8 million in Q1 2022, with the low at $35604.0 in Q1 2024.
• Historically, Gains from Investment Securities has averaged $2.1 million across 5 years, with a median of $1.5 million in 2021.
• Annual changes were most pronounced in 2021 — Gains from Investment Securities jumped 5442.9% — and 2024, when it tumbled 99.11%.
• Spero Therapeutics' Gains from Investment Securities stood at $4.9 million in 2021, then tumbled by 97.96% to $100000.0 in 2022, then soared by 2111.0% to $2.2 million in 2023, then grew by 27.31% to $2.8 million in 2024, then declined by 14.72% to $2.4 million in 2025.
• The last three Gains from Investment Securities figures came in at $2.4 million (Q4 2025), $414417.0 (Q3 2025), and $230932.0 (Q2 2025), per Business Quant data.